Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis (<1000 cases reported in the literature), characterised by tissue infiltration by CD68 + CD1a -"foamy"
histiocytes. ECD commonly causes long bone osteosclerosis, retroperitoneal (peri-aortic and peri-renal) fibrosis, central nervous system (CNS) lesions, but also involves the lung, the skin and various endocrine axes. 1 Cardiovascular manifestations are also common (~40% of the cases), and include infiltration of the myocardium (e.g., pseudotumoral atrial masses), the pericardium (e.g., pericarditis sometimes complicated by tamponade) and the aorta, with the typical aspect of "coated aorta". 2, 3 ECD patients with cardiovascular involvement are reported to have a poorer prognosis 1, 4, 5 and are therefore usually treated aggressively, but systematic studies are lacking. It is also unclear whether cardiovascular involvement only detected by imaging studies actually influences prognosis, and whether the purported adverse prognosis is due to cardiovascular lesions per se or to other factors.
With the aim of better characterising ECD-related cardiovascular lesions and their potential prognostic impact, we conducted a cross-sectional study on 23 consecutive ECD patients using a standardised protocol of cardiac magnetic resonance imaging (MRI) and MR-angiography of the thoracic aorta and epiaortic arteries. MRI was performed using a 1.5T MR Scanner (Gyroscan Intera, Philips Medical System, Best, The Netherlands) with a maximum gradient capability of 30 mT/m and maximum slew rate of 150 mT/ms. MR acquisition was triggered by ECG and included functional study by means of balanced steady-state free precession (b-SSFP) cine-MR images in the short-axis, and vertical longaxis and horizontal long-axis planes; morphologic evaluation was performed with T2-weighted (T2w) images and STIR (short time inversion recovery) T2w images in order to suppress fatty tissue signal and emphasise tissue and myocardial oedema/inflammation.
Finally three-dimensional GRE/segmented inversion recovery T1w sequences were 2 we found no MRI evidence of ECD-related valvular disease. Thoracic large artery involvement was generally characterised by perivascular thickening of the thoracic aorta and the origin of the epiaortic arteries (supplementary figure 1) , but no luminal narrowing or aneurysms were detected.
Six of the 10 patients with cardiac MRI abnormalities had cardiovascular symptoms during their disease course: in particular, patients #1, #2 and #9 had peripheral edema and dyspnea-and #2 also chest pain-due to pericarditis; patient #14 presented with peripheral edema and dyspnea due to acute cardiac failure, patient #6 palpitations and dyspnea secondary to atrial flutter, and patient #15 angina and syncope likely secondary to atherosclerotic, non-ECD related, coronary artery disease. Cardiovascular symptoms were also found in patients without cardiac MRI abnormalities, due to atherosclerosis-related ischemic heart disease (#13 and #17) and uremic pericarditis (#19) ( supplementary table   1 ). Only one patient (#6) underwent cardiac electrophysiology study (when radiofrequency ablation was performed for atrial flutter), but we could not retrieve the results of this study.
The patients received different treatments, mainly sirolimus and prednisone, 6 interferon-α, vemurafenib, and chemotherapy; there were no significant differences in the distribution of the different therapies between patients with and without cardiac MRI abnormalities (data not shown). Eight patients (seven of whom had cardiac MRI abnormalities) underwent follow-up cardiac MRI: the lesions remained stable in four patients (two treated with interferon-α, one with prednisone and one with vemurafenib), partially regressed in two (both treated with sirolimus and prednisone) (supplementary video), and progressed in one
(sequentially treated with sirolimus and vemurafenib) (supplementary table 2). Three patients died, one in the cardiac group and two in the non-cardiac group. No significant differences in overall survival were found between the two groups (log-rank test p=0.57), although it must be acknowledged that the mortality rate was low (supplementary figure 2) .
Progression-free survival, defined as time from remission to disease progression, was also similar (log-rank test p=0.63) (supplementary figure 2) . The demographic characteristics and the frequency of organ involvement did not differ between the two groups, although most manifestations tended to be more frequent in the group with cardiac abnormalities (supplementary table 3 ). When we investigated disease extension by calculating the number of involved sites, we found that patients with cardiac MRI abnormalities had a significantly higher number of (extra-cardiac) involved sites than those without cardiac lesions (p=0.0097); in particular, all patients with disseminated disease (≥ 5 sites involved) fell in the cardiac group (supplementary figure 3) . No cluster analyses have been performed in ECD, but it is known that its clinical spectrum ranges from organ-limited, asymptomatic forms to disseminated and life-threatening disease. 8 These findings demonstrate that cardiac involvement (either clinical or subclinical) is associated with a more widespread disease.
In conclusion, cardiac and angio-MRI reveals peculiar patterns of cardiac and large-vessel involvement in ECD and often allows detection of clinically silent lesions. It is therefore advisable that all ECD patients undergo cardiac and angio-MRI at the time of diagnosis, and in case of new cardiovascular manifestations or overall disease progression. In our series, MRI-detected cardiac disease did not have an impact on survival, although this finding is limited by the low mortality rate observed and should be confirmed by larger studies. However, MRI-detected cardiac involvement was clearly associated with a greater Abbreviations (in alphabetical order). -= absent; AA=ascending aorta; AArch= aortic arch; AV: atrio-ventricular; B= bone; BT=brachiocephalic trunk; CNS= central nervous system; DA= descending aorta; EF= ejection fraction; HPG: hypothalamic-pituitary gland axis; IVC= inferior vena cava; L= lung; LCCA= left common carotid artery; LSA= left subclavian artery; NA: not available; O= orbits; PA= pulmonary artery; RP=retroperitoneum; RPV= right pulmonary vein; S= skin; SVC= superior vena cava; TTD: time from symptom onset to diagnosis.
